{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:37:01Z","timestamp":1753893421350,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare and aggressive non-Hodgkin\u2019s B cell lymphoma characterized by the translocation t(11;14) (q13;32) and overexpression of <jats:italic>CCND1<\/jats:italic>. MCL is immunophenotypically identified as CD20<jats:sup>+<\/jats:sup>, CD5<jats:sup>+<\/jats:sup>, CyclinD1+, CD43<jats:sup>+<\/jats:sup>, CD10<jats:sup>\u2212<\/jats:sup>, BCL6<jats:sup>\u2212<\/jats:sup>, and CD23<jats:sup>\u2212<\/jats:sup>. It is often distinguished from B cell lymphomas of germinal center cell origin by the absence of CD10 expression. Here we report the unique clinicopathologic features of a patient with CD10<jats:sup>+<\/jats:sup> MCL with gastrointestinal involvement and review current literature identifying this unique immunophenotype.<\/jats:p>","DOI":"10.3389\/pore.2022.1610588","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:16:41Z","timestamp":1661433401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature"],"prefix":"10.3389","volume":"28","author":[{"given":"Christopher","family":"Hino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin L.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan Ran","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojtaba","family":"Akhtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle Cell Lymphoma: 2019 Update on the Diagnosis, Pathogenesis, Prognostication, and Management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"US Lymphoid Malignancy Statistics by World Health Organization Subtypes: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"20162016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/(sici)1097-0142(19980201)82:3<567::aid-cncr20>3.0.co;2-z","article-title":"Mantle Cell Lymphoma: Presenting Features, Response to Therapy, and Prognostic Factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"B4","first-page":"115","article-title":"Mantle-cell Lymphoma","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and Molecular Pathogenesis of Mantle Cell Lymphoma: Perspectives for New Targeted Therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and Epigenomic Insights into the Origin, Pathogenesis, and Clinical Behavior of Mantle Cell Lymphoma Subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I Treat Mantle Cell Lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11441","DOI":"10.18632\/oncotarget.23571","article-title":"CD10-positive Mantle Cell Lymphoma: Clinicopathologic and Prognostic Study of 30 Cases","volume":"9","author":"Xu","year":"2018","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2559.2008.03060.x","article-title":"Mantle Cell Lymphoma with Aberrant Expression of CD10","volume":"53","author":"Zanetto","year":"2008","journal-title":"Histopathology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic Variations in Mantle Cell Lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib Plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, Obinutuzumab, and Venetoclax in Relapsed and Untreated Patients with Mantle Cell Lymphoma: a Phase 1\/2 Trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging Therapies in Mantle Cell Lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on Mantle Cell Lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/aol.2019.03.01","article-title":"Mantle Cell Lymphoma Pathology Update in the 2016 WHO Classification","volume":"3","author":"Veloza","year":"2019","journal-title":"Ann Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.5858\/arpa.2017-0368-OA","article-title":"Immunophenotypic Variations in Mantle Cell Lymphoma and Their Impact on Clinical Behavior and Outcome","volume":"142","author":"Aqil","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/jclinpath-2015-202955","article-title":"CD10-positive Mantle Cell Lymphoma : Biologically Distinct Entity or an Aberrant Immunophenotype? Insight, through Gene Expression Profile in a Unique Case Series","volume":"68","author":"Akhter","year":"2015","journal-title":"J Clin Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/01.pas.0000128671.92609.af","article-title":"Aberrant Bcl6 Protein Expression in Mantle Cell Lymphoma","volume":"28","author":"Camacho","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1309\/UD2C-6JVP-WHXQ-Q217","article-title":"An Unusual Case of Leukemic Mantle Cell Lymphoma with a Blastoid Component Showing Loss of CD5 and Aberrant Expression of CD10","volume":"122","author":"Morice","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1309\/T88X-71U4-WC0R-2531","article-title":"Assessment of CD10 in the Diagnosis of Small B-Cell Lymphomas: A Multiparameter Flow Cytometric Study","volume":"117","author":"Xu","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1309\/u98advkuc26r2rja","article-title":"B-Cell Lymphomas with Coexpression of CD5 and CD10","volume":"119","author":"Dong","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of Somatic Mutations and Clonal Evolution in Mantle Cell Lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1182\/blood.v89.6.2067","article-title":"Mantle Cell Lymphoma: a Clinicopathologic Study of 80 Cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","article-title":"Longitudinal Single-Cell Profiling Reveals Molecular Heterogeneity and Tumor-Immune Evolution in Refractory Mantle Cell Lymphoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B27","first-page":"879","article-title":"Mantle Cell Lymphoma: Clinicopathologic Features and Treatments","volume":"17","author":"Kauh","year":"2003","journal-title":"Oncology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/107327481201900307","article-title":"Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Control"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/hupa.2002.30221","article-title":"From Centrocytic to Mantle Cell Lymphoma: A Clinicopathologic and Molecular Review of 3 Decades","volume":"33","author":"Swerdlow","year":"2002","journal-title":"Hum Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/10428190801947559","article-title":"Molecular Genetic Characterization Reveals New Subsets of Mantle Cell Lymphoma","volume":"49","author":"Thelander","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-2776(10)05007-8","article-title":"BCL6: Master Regulator of the Germinal center Reaction and Key Oncogene in B Cell Lymphomagenesis","volume":"105","author":"Basso","year":"2010","journal-title":"Adv Immunol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:16:45Z","timestamp":1661433405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":31,"alternative-id":["10.3389\/pore.2022.1610588"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610588","relation":{},"ISSN":["1532-2807"],"issn-type":[{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"1610588"}}